Development of olaparib-resistance prostate cancer cell lines to identify mechanisms associated with acquired resistance

HIGHLIGHTS

• who: Maxime Cahuzac et al. from the Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC H X , Canada have published the paper: Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance, in the Journal: Cancers 2022, 3877 of /2022/
• what: The study provides a new in vitro model to study PARPi resistance in PC and suggests new possible targets to reverse resistance and prolong the benefits of PARPi treatment. The analysis showed that several pathways, such as DNA repair or autophagy, may . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.